Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The Lung Immune Prognostic Index (LIPI) is associated with immune checkpoint inhibitors (ICI) outcomes across different solid tumors, particularly in non-small cell lung cancer. Data regarding the prognostic and/or predictive role of LIPI in metastatic renal cell carcinoma (mRCC) are still scarce. The aim of this study was to evaluate whether LIPI could be predictive of survival in mRCC patients.
Methods: We used patient level data from three different prospective studies (NIVOREN trial: nivolumab; TORAVA trial: VEGF/VEGFR-targeted therapy (TT); CheckMate 214: nivolumab-ipilimumab vs sunitinib). LIPI was calculated based on a derived neutrophils/(leukocyte-neutrophil) ratio > 3 and lactate-dehydrogenase >upper limit of normal, classifying patients into three groups (LIPI good, 0 factors;LIPI intermediate (int), 1 factor;LIPI poor, 2 factors) and/or into two groups (LIPI good, 0 factors;LIPI int/poor, 1-2 factors) according to trial sample size. Primary and secondary endpoints were overall survival (OS) and progression-free survival (PFS).
Results: In the Nivolumab dataset (n = 619), LIPI was significantly associated with OS (LIPI-good 30.1 vs 13.8 months in the LIPI int/poor; HR= 0.47) and PFS (HR=0.74). In the VEGF/VEGFR-TT dataset (n = 159), only a correlation with PFS was observed. In the CheckMate214 dataset (n = 1084), LIPI was significantly associated with OS (nivolumab-ipilimumab OS LIPI good vs int/poor: HR=0.55, p < 0.0001; sunitinib: OS LIPI good vs int/poor: 0.38, p < 0.0001) in both treatment groups in univariate and multivariate analysis.
Conclusions: Pretreatment-LIPI correlated with worse survival outcomes in mRCC treated with either ICI or antiangiogenic therapy, confirming LIPI's prognostic role in mRCC irrespective of systemic treatment used.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085868 | PMC |
| http://dx.doi.org/10.1016/j.ejca.2024.114048 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Profiling Listeria monocytogenes in Hummus, Fresh Produce, and Food Processing Environments in the Western Cape, South Africa.
Microbiologyopen
October 2025
Department of Food Science, Stellenbosch University, Stellenbosch, Western Cape, South Africa.
Listeria monocytogenes is pervasive in agricultural environments and difficult to eradicate from food-processing facilities. Consequently, various foods become contaminated, posing health risks to immunocompromised individuals. This surveillance study aimed to enhance the understanding of the genetic diversity, virulence, plasmid content, sanitizer tolerance, and antibiotic resistance of L.
View Article and Find Full Text PDFThe survival analysis of stage III and IV inoperable lung large cell neuroendocrine carcinoma and the role of LIPI in immunological stratification.
Lung Cancer
August 2025
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou, China; Guangzhou Institute of Respiratory Health, Guangzhou, C
Background: Large cell neuroendocrine carcinoma (LCNEC) represents a rare and unique type of lung tumor with an unfavorable prognosis. It is essential to summarize the treatment modalities and prognosis for inoperable stage III and IV LCNEC, explore the role of frontline immunotherapy, and examine the stratification role of the Lung Immune Prognostic Index (LIPI) and its relationship with the tumor microenvironment (TME).
Methods: This study retrospectively analyzed 160 patients with inoperable lung LCNEC (L-LCNEC) admitted to three hospitals from December 2012 to November 2023.
Exploring the metabolic-immune score in advanced NSCLC treated with immunotherapy.
Sci Rep
August 2025
Faculty of Medicine, Department of Medical Oncology, Ankara University, Cebeci, Ankara, 06100, Türkiye, Turkey.
Identifying reliable prognostic markers in patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) is critical for clinical decision-making. This study introduces the Metabolic and Immune Score (MIS), a novel scoring system combining metabolic and inflammatory markers. A retrospective analysis was conducted on 56 patients with advanced NSCLC treated with ICIs between January 2018 and January 2024.
View Article and Find Full Text PDFMechanism of Lipi Jiangzhuo Decoction in Improving Metabolic Dysfunction-Associated Steatohepatitis Through the PERK/PINK1/GPx4 Pathway.
J Inflamm Res
August 2025
Foreign Languages College, Shandong University of Traditional Chinese Medicine, Jinan City, Shandong Province, People's Republic of China.
Background: Metabolic dysfunction-associated steatohepatitis (MASH) is characterized primarily by hepatocyte lipoapoptosis and hepatic inflammation, frequently developing from overweight/obesity. To date, no specific therapeutics exist to reverse MASH. Although resmetirom has been approved in some regions, patients in many Asian countries, including China, still lack access to approved pharmacotherapy for MASH.
View Article and Find Full Text PDFThe lung immune prognostic index stratifies the occurrence of checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients: a multi-institutional cohort study.
Br J Cancer
August 2025
Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Background: Lung immune prognostic index (LIPI) is associated with survival outcomes in patients with non-small cell lung cancer (NSCLC) receiving immunotherapy, but the association with the occurrence of checkpoint inhibitor pneumonitis (CIP) is unclear.
Methods: We retrospectively included 1824 patients with advanced NSCLC who received immune checkpoint inhibitors (ICIs) at two institutions. Cox regression analysis and cumulative incidence curve were used to evaluate the predictive value of LIPI.